A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea

In VitroActivity of the New Fluoroketolide Solithromycin (CEM-101) against Macrolide-Resistant and -Susceptible Mycoplasma genitalium Strains

(2014) Jørgen Skov Jensen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Duration of Polymerase Chain Reaction–Detectable DNA After Treatment of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis Infections in Women

(2014) James A. Williams et al.   SEXUALLY TRANSMITTED DISEASES

Neisseria gonorrhoeae Treatment Failure and Susceptibility to Cefixime in Toronto, Canada

(2013) Vanessa G. Allen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Emergence of Increased Azithromycin Resistance During Unsuccessful Treatment of Neisseria gonorrhoeae Infection With Azithromycin (Portland, OR, 2011)

(2013) Olusegun O. Soge et al.   SEXUALLY TRANSMITTED DISEASES

In VitroActivity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical Neisseria gonorrhoeae Isolates and International Reference Strains, Including Those with High-Level Antimicrobial Resistance: Potential Treatment Option for Gonorrhea?

(2012) Daniel Golparian et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Selective Protein Synthesis by Ribosomes with a Drug-Obstructed Exit Tunnel

(2012) Krishna Kannan et al.   CELL

Binding and Action of CEM-101, a New Fluoroketolide Antibiotic That Inhibits Protein Synthesis

(2010) B. Llano-Sotelo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Re-Evaluating the Treatment of Nongonococcal Urethritis: Emphasizing Emerging Pathogens-A Randomized Clinical Trial

(2010) J. R. Schwebke et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Activity of CEM-101, a New Fluoroketolide Antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae

(2009) P. M. Roblin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY